Regencell Bioscience Holdings Limited RGC
6.17
0.00
0.00%
as of 25 Sep
- Market cap
- $3.1B
- P/E
- 0.0×
Follow RGC
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '23 | Jun '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(336.98%) | 0.00% | 0.00% | 0.00% | |
| (207.77%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(112.86%) | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(12.19) | (15.81) | (18.31) | (14.67) | |
Capital Expenditures |
(0.82) | (0.81) | (0.97) | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(48.28%) | (92.70%) | (177.78%) | (410.18%) | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Operating CF/Net income |
0.84 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.53 | 0.84 | 0.77 | 0.00 | |
Capex/Depreciation |
(1.70) | (1.05) | (1.17) | — | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates